Euclidean Technologies Management’s AbbVie ABBV Stock Holding History

Euclidean Technologies Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$330K	Hold	2,071	–	–	0.3%	56
2022 Q4	$335K	Hold	2,071	–	–	0.32%	50
2022 Q3	$278K	Hold	2,071	–	–	0.31%	52
2022 Q2	$317K	Hold	2,071	–	–	0.33%	51
2022 Q1	$336K	Hold	2,071	–	–	0.31%	55
2021 Q4	$280K	Hold	2,071	–	–	0.23%	58
2021 Q3	$223K	Hold	2,071	–	–	0.19%	64
2021 Q2	$233K	Buy	+2,071	New	+$233K	0.19%	69

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Euclidean Technologies Management's ABBV Position: Q1 2023 in Review

Euclidean Technologies Management held its AbbVie (ABBV) position steady in Q1 2023 at 2,071 shares worth $330K. The position accounts for 0.3% of the portfolio, ranked #56.

Euclidean Technologies Management first reported a position in ABBV in Q2 2021 and has held it in 8 quarters since. The position peaked at $336K in Q1 2022. 3,138 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

Euclidean Technologies Management held 2,071 shares of AbbVie worth $330K as of Q1 2023.
Euclidean Technologies Management left its AbbVie share count unchanged in Q1 2023.
AbbVie made up 0.3% of Euclidean Technologies Management's portfolio in Q1 2023, its #56 holding.
Euclidean Technologies Management first reported a position in AbbVie in Q2 2021 and has held it in 8 quarters since.
Euclidean Technologies Management's AbbVie position peaked at $336K in Q1 2022.
3,138 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on Euclidean Technologies Management's 13F filing for Q1 2023, filed 26 Apr 2023.